Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025272 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT00025272: Completed Phase 2 study of Lung Cancer, sponsored by Wake Forest University Health Sciences.
NCT00025272 is a Phase 2 study of Lung Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025272, a Phase 2 study of Lung Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, and etoposide in treating patients who have extensive-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG etoposide
- RADIATION radiation therapy
- DRUG topotecan hydrochloride
Study Locations (5)
North Carolina
- Southeastern Medical Oncology Center - Goldsboro
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
South Carolina
- CCOP - Greenville - Greenville
- CCOP - Upstate Carolina - Spartanburg
Virginia
- MBCCOP - Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2001-11-01 |
| Est. Completion | 2005-01-18 |
| Phase | Phase 2 |
What the finished NCT00025272 record still lists
NCT00025272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00025272 lists 5 locations in 3 states (North Carolina, South Carolina, Virginia).
Frequently Asked Questions
What is clinical trial NCT00025272 about?
NCT00025272 is a clinical study titled "Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, a...
What is the current status of trial NCT00025272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2001-11-01. Estimated completion is 2005-01-18.
What conditions does trial NCT00025272 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00025272?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00025272?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025272 being conducted?
This trial has 5 study locations across North Carolina, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00025272's enrollment target sits among peer trials
14 380th of 409 higher than 28 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy